Targeting drug delivery to improve organ transplant outcomes
Official title: Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium
Funded at Yale University · NIH-10979986 · Data updated 2026-11-12
This study is exploring a new way to help organ transplants work better by using tiny particles to deliver special RNA directly to the cells in the transplanted organs, which could help prevent the body from rejecting them and reduce the need for strong medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $642,639 |
| NIH project number | 1R01AI175206-01A1 |
| Project ID | NIH-10979986 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are scheduled to receive an organ transplant and may be at risk for acute rejection.
✕Less likely to help
Patients who are not candidates for organ transplantation or those with contraindications to immunosuppressive therapy may not benefit from this research.
What this research studies
This research focuses on enhancing the success of organ transplants by developing nanoparticles that deliver therapeutic RNA directly to the endothelial cells of transplanted organs. By preventing the expression of specific proteins that trigger immune rejection, the approach aims to reduce inflammation and improve graft survival. Patients undergoing organ transplants may benefit from this innovative method, which seeks to minimize the need for systemic immunosuppression. The research involves both laboratory experiments and testing on human vessel segments to evaluate the effectiveness of the nanoparticle delivery system.
Why it matters
Potential benefit: If successful, this research could significantly improve the longevity and success rates of organ transplants.
How similar studies have gone: Previous research has shown promise in using targeted nanoparticle delivery systems for therapeutic applications, indicating potential for success in this novel approach.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Pober, Jordan S — Yale University
- Study coordinator: Pober, Jordan S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.